Cardinal Health to Prepare NETSPOT™ Doses for Advanced Accelerator Applications
June 09 2016 - 7:51AM
Advanced Accelerator Applications S.A.
(NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist
in Molecular Nuclear Medicine (MNM), today announced that it has
selected Cardinal Health, Inc. (NYSE:CAH), a healthcare services
company operating the largest radiopharmaceutical network in the
United States, to supply gallium 68 (Ga 68) dotatate doses prepared
with a novel kit to U.S. hospitals and imaging centers.
NETSPOTTM (formerly known as Somakit-TATE) is a
patented kit recently approved by the U.S. Food and Drug
Administration (“FDA”) for the preparation of Ga 68 dotatate for
injection, for the localization of somatostatin receptor positive
neuroendocrine tumors in adult and pediatric patients using
Positron Emission Tomography (“PET“). The product has received
orphan drug designation from the U.S. Food and Drug Administration
(“FDA“).
Cardinal Health’s extensive U.S. network of
radiopharmaceutical manufacturing facilities will prepare and
deliver NETSPOTTM patient doses to advanced medical imaging sites
in key metropolitan areas where high demand is anticipated. This
partnership makes Cardinal Health the second radiopharmacy network
that will participate in the NETSPOTTM supply chain, after the
announcement of the Zevacor Pharma partnership earlier this
year.
“We believe that NETSPOTTM has the potential to
improve the accuracy of diagnosis while reducing radiation exposure
for patients compared to the existing standard,” said Stefano
Buono, Chief Executive Officer of AAA. “We are pleased to have
signed this non-exclusive agreement with Cardinal Health for the
preparation and delivery of NETSPOTTM. We believe that Cardinal
Health’s extensive footprint, and deep expertise in preparation of
kit based products, will make it an excellent partner in creating
broad availability of this innovative product. We believe the
establishment of broadly available doses of Ga 68
radiopharmaceuticals will also mark an important milestone in the
development of PET imaging, a development similar to the
establishment of unit dose supply of Fluorine-18 labeled
radiopharmaceuticals in the early 2000’s.”
About
NETSPOTTM
NETSPOTTM is a novel patented kit developed by
AAA for the preparation of gallium Ga 68 dotatate for injection,
for localization of somatostatin receptor positive neuroendocrine
tumors (NETs) in adult and pediatric patients using Positron
Emission Tomography (“PET“). The kit has been designated as an
orphan drug by the EMA and the FDA. For full prescribing
information for NETSPOTTM please refer to:
http://go.usa.gov/cSywA.
About Advanced Accelerator
Applications
Advanced Accelerator Applications (AAA) is an
innovative radiopharmaceutical company that develops, produces and
commercializes Molecular Nuclear Medicine (MNM) products. AAA’s
lead therapeutic product candidate, Lutathera, is a novel MNM
compound that AAA is currently developing for the treatment of
Neuro Endocrine Tumors, a significant unmet medical need. Founded
in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France.
AAA currently has 20 production and R&D facilities able to
manufacture both diagnostics and therapeutic MNM products, and has
over 440 employees in 13 countries (France, Italy, UK, Germany,
Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium,
Israel, U.S. and Canada). AAA reported sales of €88.6 million in
2015 (+26.8% vs. 2014) and sales of €26.9 million for 1Q 2016
(+29.6% vs. 1Q15). AAA is listed on the Nasdaq Global Select Market
under the ticker “AAAP”. For more information please visit:
www.adacap.com.
Cautionary Statement Regarding
Forward-Looking Statements
This press release may contain forward-looking
statements. All statements, other than statements of historical
facts, contained in this press release, including statements
regarding the Company's strategy, future operations, future
financial position, future revenues, projected costs, prospects,
plans and objectives of management, are forward-looking statements.
The words "anticipate," "believe," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Forward-looking statements reflect the Company's current
expectation regarding future events. These forward-looking
statements involve risks and uncertainties that may cause actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not
limited to, changing market conditions, the successful and timely
completion of clinical studies, the timing of our submission of
applications for regulatory approvals, EMA, FDA and other
regulatory approvals for our product candidates, the occurrence of
side effects or serious adverse events caused by or associated with
our products and product candidates; our ability to procure
adequate quantities of necessary supplies and raw materials for
Lutathera and other chemical compounds acceptable for use in our
manufacturing processes from our suppliers; our ability to organize
timely and safe delivery of our products or product candidates by
third parties; any problems with the manufacture, quality or
performance of our products or product candidates; the rate and
degree of market acceptance and the clinical utility of Lutathera
and our other products or product candidates; our estimates
regarding the market opportunity for Lutathera, our other product
candidates and our existing products; our anticipation that we will
generate higher sales as we diversify our products; our ability to
implement our growth strategy including expansion in the U.S.; our
ability to sustain and create additional sales, marketing and
distribution capabilities; our intellectual property and licensing
position; legislation or regulation in countries where we sell our
products that affect product pricing, taxation, reimbursement,
access or distribution channels; and general economic, political,
demographic and business conditions in Europe, the U.S. and
elsewhere. Except as required by applicable securities laws, we
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts:
AAA Media Relations
Véronique Mermet
Communications Officer
info@adacap.com
Tel: +33 (0)4 50 99 30 70
AAA Investor Relations
Jordan Silverstein
Director of Investor Relations
jordan.silverstein@adacap.com
Tel: + 1-212-235-2394
Media inquiries
FTI Consulting
Shauna Elkin
shauna.elkin@fticonsulting.com
Tel: +1-212-850-5613
Axess Public Relations (Italy)
Dario Francolino
dario.francolino@axesspr.com
Tel: +39 3488818029
Cardinal Health (NYSE:CAH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cardinal Health (NYSE:CAH)
Historical Stock Chart
From Sep 2023 to Sep 2024